Bernstein initiated coverage on Insulet with a new price target
$PODD
Medical/Dental Instruments
Health Care
Bernstein initiated coverage of Insulet with a rating of Outperform and set a new price target of $300.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/6/2024 | $300.00 | Outperform | Bernstein |
| 5/30/2024 | $235.00 | Buy | Redburn Atlantic |
| 5/7/2024 | $200.00 | Peer Perform → Outperform | Wolfe Research |
| 12/21/2023 | $180.00 → $238.00 | Neutral → Outperform | Robert W. Baird |
| 12/4/2023 | $185.00 → $234.00 | Equal-Weight → Overweight | Morgan Stanley |
| 10/2/2023 | $260.00 → $240.00 | Hold → Buy | Jefferies |
| 8/21/2023 | $320.00 → $219.00 | Outperform → Neutral | Robert W. Baird |
| 8/21/2023 | $273.00 → $265.00 | Neutral → Buy | Citigroup |
In the preceding three months, 7 analysts have released ratings for Insulet (NASDAQ:PODD), presenting a wide array of perspectives from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 2 1 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $225.14, along with a high estimate of $260.00 and a low estimate of $200.00. Highlig
Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and maintains $234 price target.
Insulet (NASDAQ:PODD) has outperformed the market over the past 15 years by 12.29% on an annualized basis producing an average annual return of 24.43%. Currently, Insulet has a market capitalization of $13.66 billion. Buying $1000 In PODD: If an investor had bought $1000 of PODD stock 15 years ago, it would be worth $26,248.99 today based on a price of $195.03 for PODD at the time of writing. Insulet's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
Raising Full Year Revenue and Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended September 30, 2024. "We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead, President and Chief Executive Officer. "Omnipod 5 is the first and only automated insulin delivery system in the U.S. for both type 1 and type 2 diabetes, following recent FDA clearance for the type 2 label indication. Insulet leads the industry, and Omnipod 5 is revolutionizing diabetes care worldwide. I am proud of ou
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2024 on November 7, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203
Raising Full Year Revenue, Gross Margin and Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2024. Second Quarter Financial Highlights: Second quarter 2024 revenue of $488.5 million, up 23.2%, or 23.4% in constant currency1, compared to $396.5 million in the prior year, exceeds the high end of the Company's guidance range of 18% in constant currency due to revenue outperformance for all product lines Total Omnipod revenue of $480.4 million, an increase of 26.3%, or 26.5% in constant curr
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
8-K - INSULET CORP (0001145197) (Filer)
10-Q - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S. "We are excited to announce that Omnipod 5, the only AID system indicated for both type 1 and type 2 diabetes, is now integrated with Abbott's FreeStyle Libre 2 Plus sensor in the U.S. This latest innovation will allow millions of Americans who take insulin the ability to get started on Pod th
Insulet Corporation (NASDAQ:PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 6th Annual Wolfe Research Healthcare Conference in New York City on Wednesday, November 20, 2024 at 12:00 p.m. The Nasdaq 51st Investor Conference in London on Tuesday, December 10, 2024 at 5:30 a.m. The J.P. Morgan 43rd Annual Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 6:45 p.m. To listen to the live audio webcasts of the presentations, please visit investors.insulet.com/events. Replays of the webcasts will als
Raising Full Year Revenue and Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended September 30, 2024. "We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead, President and Chief Executive Officer. "Omnipod 5 is the first and only automated insulin delivery system in the U.S. for both type 1 and type 2 diabetes, following recent FDA clearance for the type 2 label indication. Insulet leads the industry, and Omnipod 5 is revolutionizing diabetes care worldwide. I am proud of ou
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
Bernstein initiated coverage of Insulet with a rating of Outperform and set a new price target of $300.00
Redburn Atlantic initiated coverage of Insulet with a rating of Buy and set a new price target of $235.00
Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $200.00
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also incl
Medical Device Leaders Shlomi Nachman and Timothy Scannell to join Board of DirectorsBOSTON, July 16, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, today announced the following appointments to the Company's Board of Directors, effective July 11, 2024: Shlomi Nachman, former Company Group Chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson's Medical Devices sectorTimothy Scannell, former President and Chief Operating Officer of Stryker"We are excited